Released May 9, 2019, after the close
10-Q filed May 9, 2019, 39 days after period end · 0001144204-19-024904
Q1 2019 · 10-Q
Revenue$3.89M$3.89M +9.0% vs Q1 2018+4.0% vs Q4 2018
Net Income-$27.05M-$27.05M N/M vs Q1 2018N/M vs Q4 2018
EPS Diluted-$1.05-$1.05 N/M vs Q1 2018N/M vs Q4 2018
Operating Income-$28,336,000N/M
Operating Cash Flow-$23,939,000N/M
Free Cash Flowderived-$25,427,000N/M
Margins · derived
Operating margin-729.4%−261.7 pt vs Q1 2018
Net margin-696.3%−240.5 pt vs Q1 2018
What the release said
The release
Same quarter
| Metric | Q1 2019 | Q1 2018 | Q1 2017 | Q1 2016 |
|---|---|---|---|---|
| Revenue | $3.89M | $3.57M | $684.00K | — |
| Net Income | -$27.05M | -$16.25M | -$13.93M | -$10.99M |
| EPS Diluted | -$1.05 | -$0.80 | -$810.00 | -$0.64 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR